Efficacy of vancomycin in treatment of pneumonia caused by methicillin-resistant Staphylococcus aureus in the elderly patients
- VernacularTitle:万古霉素治疗耐甲氧西林金黄色葡萄球菌肺炎老年患者的疗效分析
- Author:
Hong CHEN
;
Xiaohui LI
;
Weimin LI
;
Bojiang CHEN
- Publication Type:Journal Article
- Keywords:
vancomycin;
linezolid;
methicillin-resistant Staphylococcus aureus;
pneumonia,elderly
- From:
Chinese Journal of Infection and Chemotherapy
2015;(5):434-438
- CountryChina
- Language:Chinese
-
Abstract:
Objective To examine the efficacy and safety profile of vancomycin in treatment of pneumonia caused by methicillin‐resistant Staphylococcus aureus (MRSA)in the elderly patients .Methods The clinical data were retrospectively analyzed for 40 elderly patients with MRSA‐induced pneumonia .The patients were analyzed in terms of treatment regimen ,vancomycin (n=25)or linezolid (n= 15) .Vancomycin was administered intravenously at dose of 0 .5 g every 8 hours for 10‐14 days ,while linezolid was given intravenously at dose of 0 .6 g every 12 hours for 10‐14 days .The clinical efficacy and adverse events were compared between the two groups .Results The overall efficacy rate was 72 .0% in vancomycin group ,and 86 .7% in linezolid group (P>0 .05) .After treatment ,the clearance rate of MRSA was 76 .0% in vancomycin group ,and 80 .0% in linezolid group (P>0 .05) .Reduction of platelet counts by more than 25% was found in 3 (20 .0% )patients treated with linezolid ,but none patient in vancomycin group .Acute renal dysfunction was reported in 4 (16 .0% )patients in vancomycin group but not identified in linezolid group .Conclusions Vancomycin has positive effect in the treatment of MRSA pneumonia in the elderly . Vancomycin treatment is associated with lower risk of thrombocytopenia ,but relatively higher risk of acute renal dysfunction .
